256 related articles for article (PubMed ID: 2572592)
1. Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate.
Assaraf YG; Molina A; Schimke RT
J Biol Chem; 1989 Nov; 264(31):18326-34. PubMed ID: 2572592
[TBL] [Abstract][Full Text] [Related]
2. A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells.
Sharma RC; Assaraf YG; Schimke RT
Cancer Res; 1991 Jun; 51(11):2949-59. PubMed ID: 1674447
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Assaraf YG; Molina A; Schimke RT
J Natl Cancer Inst; 1989 Feb; 81(4):290-4. PubMed ID: 2521520
[TBL] [Abstract][Full Text] [Related]
4. Mutations leading to antifolate resistance in Chinese hamster ovary cells after exposure to the alkylating agent ethylmethanesulfonate.
Fanin R; Banerjee D; Volkenandt M; Waltham M; Li WW; Dicker AP; Schweitzer BI; Bertino JR
Mol Pharmacol; 1993 Jul; 44(1):13-21. PubMed ID: 8341268
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric characterization of antifolate resistance in cultured mammalian cells using fluoresceinated methotrexate and daunorubicin.
Sherwood SW; Assaraf YG; Molina A; Schimke RT
Cancer Res; 1990 Aug; 50(16):4946-50. PubMed ID: 2143099
[TBL] [Abstract][Full Text] [Related]
6. Differential reversal of lipophilic antifolate resistance in mammalian cells with modulators of the multidrug resistance phenotype.
Assaraf YG; Borgnia MJ
Anticancer Drugs; 1993 Jun; 4(3):395-406. PubMed ID: 8102912
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine.
Assaraf YG; Slotky JI
J Biol Chem; 1993 Feb; 268(6):4556-66. PubMed ID: 8440739
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the coexisting multiple mechanisms of methotrexate resistance in mouse 3T6 R50 fibroblasts.
Assaraf YG; Feder JN; Sharma RC; Wright JE; Rosowsky A; Shane B; Schimke RT
J Biol Chem; 1992 Mar; 267(9):5776-84. PubMed ID: 1372892
[TBL] [Abstract][Full Text] [Related]
9. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates.
Fry DW; Besserer JA
Cancer Res; 1988 Dec; 48(24 Pt 1):6986-91. PubMed ID: 2973370
[TBL] [Abstract][Full Text] [Related]
10. Expression of dihydrofolate reductase and multidrug resistance genes in trimetrexate-resistant human leukemia cell lines.
Li XK; Kobayashi H; Holland JF; Ohnuma T
Leuk Res; 1993 Jun; 17(6):483-90. PubMed ID: 8099375
[TBL] [Abstract][Full Text] [Related]
11. Effect of direct suppression of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by antifolates. Influence of degree of dihydrofolate reductase inhibition.
Seither RL; Trent DF; Mikulecky DC; Rape TJ; Goldman ID
J Biol Chem; 1991 Mar; 266(7):4112-8. PubMed ID: 1825652
[TBL] [Abstract][Full Text] [Related]
12. Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Cancer Lett; 1995 Jan; 88(1):93-9. PubMed ID: 7850779
[TBL] [Abstract][Full Text] [Related]
13. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
Matherly LH; Barlowe CK; Goldman ID
Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
[TBL] [Abstract][Full Text] [Related]
14. Biochemical pharmacology of the lipophilic antifolate, trimetrexate.
Jackson RC; Fry DW; Boritzki TJ; Besserer JA; Leopold WR; Sloan BJ; Elslager EF
Adv Enzyme Regul; 1984; 22():187-206. PubMed ID: 6236675
[TBL] [Abstract][Full Text] [Related]
15. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Bram E; Ifergan I; Shafran A; Berman B; Jansen G; Assaraf YG
Cancer Chemother Pharmacol; 2006 Dec; 58(6):826-34. PubMed ID: 16612649
[TBL] [Abstract][Full Text] [Related]
16. Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells.
Seither RL; Trent DF; Mikulecky DC; Rape TJ; Goldman ID
J Biol Chem; 1989 Oct; 264(29):17016-23. PubMed ID: 2529254
[TBL] [Abstract][Full Text] [Related]
17. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent.
Allegra CJ; Kovacs JA; Drake JC; Swan JC; Chabner BA; Masur H
J Exp Med; 1987 Mar; 165(3):926-31. PubMed ID: 2950200
[TBL] [Abstract][Full Text] [Related]
18. Differential alterations of dihydrofolate reductase gene in human leukemia cell lines made resistant to various folate analogues.
Miyachi H; Takemura Y; Kobayashi H; Ando K; Ando Y
Jpn J Cancer Res; 1993 Jan; 84(1):9-12. PubMed ID: 8449831
[TBL] [Abstract][Full Text] [Related]
19. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.
Arkin H; Ohnuma T; Kamen BA; Holland JF; Vallabhajosula S
Cancer Res; 1989 Dec; 49(23):6556-61. PubMed ID: 2573416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
